Imatinib Mesylate as Add-On Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

Study Questions:

Imatinib, the anti-proliferative agent that targets tyrosine kinase inhibitors (TKI), is a platelet-derived growth factor inhibitor. Is imatinib efficacious in treating patients with pulmonary arterial hypertension (PAH)?